Practice Patterns and Predictors of Followup Imaging after a Negative Bone Scan in Men with Castration Resistant Prostate Cancer: Results from the SEARCH Database
Abstract
Purpose:
We investigated imaging practice patterns in men with nonmetastatic (M0) castration resistant prostate cancer.
Materials and Methods:
We analyzed data on 247 patients with documented M0 CRPC from the SEARCH database. Patients were selected regardless of primary treatment modality and all had a negative bone scan after a castration resistant prostate cancer diagnosis. Cox models were used to test associations of time to a second imaging test with several demographic and clinical factors.
Results:
During a median followup of 29.0 months (IQR 12.9–43.5) after a post-castration resistant prostate cancer bone scan was negative, 190 patients (77%) underwent a second imaging test. On univariable analysis patients with higher prostate specific antigen (HR 1.13, p = 0.016), shorter prostate specific antigen doubling time (HR 0.79, p <0.001) and faster prostate specific antigen velocity (HR 1.01, p <0.001) were more likely to undergo a second imaging test. Treatment center was also a significant predictor of a second imaging test (p = 0.010). No other factor was a significant predictor. Results were similar on multivariable analysis. It was estimated that approximately 20% of men with a prostate specific antigen doubling time of less than 3 months did not undergo an imaging test in the first year after a post-castration resistant prostate cancer negative bone scan. However, 50% of patients with prostate specific antigen doubling time 15 months or greater underwent a second imaging test in the first year.
Conclusions:
Clinicians use some known predictors of positive imaging tests to determine which patients with M0 castration resistant prostate cancer undergo a second imaging test . However, there may be under imaging in those at high risk and over imaging in those at low risk. Further studies are needed to identify risk factors for metastasis and form clear imaging guidelines in patients with M0 castration resistant prostate cancer.
References
- 1 : CUA-CUOG guidelines for the management of castration-resistant prostate cancer (CRPC): 2013 update. Can Urol Assoc J2013; 7: 231. Google Scholar
- 2 : Use of bone scan during initial prostate cancer workup, downstream procedures, and associated Medicare costs. Int J Radiat Oncol Biol Phys2014; 89: 243. Google Scholar
- 3 : Updated trends in imaging use in men diagnosed with prostate cancer. Prostate Cancer Prostatic Dis2014; 17: 246. Google Scholar
- 4 : Inappropriate utilization of radiographic imaging in men with newly diagnosed prostate cancer in the United States. Cancer2012; 118: 1260. Google Scholar
- 5 : Bone scan overuse in staging of prostate cancer: an analysis of a Veterans Affairs cohort. Urology2011; 77: 1330. Google Scholar
- 6 : Overuse of imaging for staging low risk prostate cancer. J Urol2011; 185: 1645. Link, Google Scholar
- 7 : The population level prevalence and correlates of appropriate and inappropriate imaging to stage incident prostate cancer in the Medicare population. J Urol2012; 187: 97. Link, Google Scholar
- 8 : Disease and host characteristics as predictors of time to first bone metastasis and death in men with progressive castration-resistant nonmetastatic prostate cancer. Cancer2011; 117: 2077. Google Scholar
- 9 : Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. J Clin Oncol2005; 23: 2918. Google Scholar
- 10 : Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling time. J Clin Oncol2013; 31: 3800. Google Scholar
- 11 : Predicting bone scan positivity after biochemical recurrence following radical prostatectomy in both hormone-naive men and patients receiving androgen-deprivation therapy: results from the SEARCH database. Prostate Cancer Prostatic Dis2014; 17: 91. Google Scholar
- 12 : End points and outcomes in castration-resistant prostate cancer: from clinical trials to clinical practice. J Clin Oncol2011; 29: 3695. Google Scholar
- 13 : Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA2005; 294: 433. Google Scholar
- 14 : Challenges and recommendations for early identification of metastatic disease in prostate cancer. Urology2014; 83: 664. Google Scholar
- 15 Moreira DM, Howard LE, Sourbeer KN et al: Predictors of time to metastasis in non-metastatic castration-resistant prostate cancer. Presented at annual meeting of American Urological Association, Orlando, Florida, May 16–21, 2014. Google Scholar
- 16 : Medical center characteristics associated with PSA screening in elderly veterans with limited life expectancy. J Gen Intern Med2012; 27: 653. Google Scholar
- 17 : Comorbidities, treatment and ensuing survival in men with prostate cancer. J Gen Intern Med2012; 27: 492. Google Scholar
- 18 : Regional collaboration to improve radiographic staging practices among men with early stage prostate cancer. J Urol2011; 186: 844. Link, Google Scholar
